vTv Therapeutics Inc. (VTVT) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in vTv Therapeutics (VTVT) by buying shares or fractional shares at any major US broker, though it is a very small, speculative clinical-stage biotech rather than a mainstream holding. vTv is developing cadisegliatin (formerly TTP399), an oral, liver-selective glucokinase activator being tested as a potential first-in-class add-on therapy for type 1 diabetes, currently in a US Phase 3 trial called CATT1 and carrying FDA Breakthrough Therapy designation. The single most important thing to understand is that this is a binary, pre-revenue story: the stock is a micro-cap whose value hinges almost entirely on clinical trial results and regulatory outcomes for a small number of drug candidates, so it can move dramatically on data and carries a real risk of failure or dilution.
VTVT stock price
As of 2026-07-14, vTv Therapeutics Inc. (VTVT) last closed at $32.30, up 93.3% over the past year. Over the past 52 weeks it has traded between $14.00 and $42.72.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or vTv Therapeutics Inc.'s investor relations page. Walnut is informational, not investment advice.
What does vTv Therapeutics Inc. (VTVT) do?
vTv Therapeutics is a clinical-stage biopharmaceutical company, meaning it has no approved products and no meaningful product revenue; its value rests on the potential of drug candidates still in testing. Its lead program is cadisegliatin (previously known as TTP399), an oral small-molecule, liver-selective glucokinase activator being developed as a potential first-in-class oral adjunctive treatment for type 1 diabetes, taken alongside insulin. The drug produced positive Phase 2 results (the Simplici-T1 study) showing improvements in blood-sugar control and time in range, and it has been granted Breakthrough Therapy designation by the FDA, a status meant to speed development of promising therapies. It is now being evaluated in a US Phase 3 trial, CATT1, with enrollment expected to complete in the second half of 2026.
As a micro-cap biotech (market value roughly in the low hundreds of millions), vTv depends on cash reserves, partnerships, and periodic financings to fund its trials rather than on operating profits. In early 2026 it amended a licensing agreement with Newsoara Biopharma, granting global rights to its PDE4 inhibitor HPP737 in exchange for a $20 million upfront payment plus potential milestones and royalties, which bolstered its cash position (reported around $98 million in the first quarter of 2026) and helped fund operations toward the CATT1 data readout. vTv is also pursuing cadisegliatin in type 2 diabetes through a Phase 2 collaboration with M42's IROS in the United Arab Emirates. Its historical pipeline has included out-licensed programs, reflecting a strategy of partnering assets to raise non-dilutive capital.
What's driving vTv Therapeutics Inc. (VTVT)?
1. Cadisegliatin Phase 3 in type 1 diabetes
The core of the story is cadisegliatin, an oral glucokinase activator in the CATT1 Phase 3 trial for type 1 diabetes, with enrollment expected to finish in the second half of 2026. Positive Phase 2 data and FDA Breakthrough Therapy designation support the case for a potential first-in-class oral add-on to insulin. Because vTv's value hinges so heavily on this program, the trial's progress and eventual topline results are the dominant catalyst for the stock.
2. Cash runway and non-dilutive funding
As a pre-revenue biotech, vTv lives on its cash balance and financings. A first-quarter 2026 cash position near $98 million, aided by a $20 million upfront payment from amending the Newsoara license for HPP737, was described as sufficient to reach the CATT1 topline readout. Extending runway through data via partnership cash rather than share sales is a positive, but any shortfall could force dilutive fundraising before or after results.
3. Partnering and pipeline breadth
vTv has a history of out-licensing assets to raise non-dilutive capital, including the HPP737 PDE4 inhibitor licensed globally to Newsoara (up to roughly $115 million in potential milestones plus royalties) and earlier regional deals. It is also testing cadisegliatin in type 2 diabetes via a Phase 2 collaboration with M42's IROS in the UAE. These partnerships add optionality and funding, though the economics to vTv depend on milestones and approvals that are far from certain.
4. Breakthrough Therapy status and first-in-class potential
Cadisegliatin's FDA Breakthrough Therapy designation is meant to expedite development and review of drugs that may offer substantial improvement over existing options. If approved, it could be a first-in-class oral adjunct for type 1 diabetes, a market with few oral options beyond insulin. This differentiation underpins the bull case, but designation is not approval, and the drug must still clear Phase 3 and regulatory review.
What are the risks to vTv Therapeutics Inc. (VTVT)?
The overriding risk is binary clinical and regulatory failure: as a pre-revenue micro-cap, vTv's value depends on a small number of drug candidates, and a disappointing CATT1 result or an FDA setback could sharply cut the stock. Financing risk is acute because the company funds trials from cash and partnerships rather than profits, so any runway shortfall could force dilutive equity raises that hurt existing shareholders. Being a micro-cap, the shares can be thinly traded and highly volatile, amplifying moves on any news. Breakthrough Therapy designation speeds but does not guarantee approval, and even an approved drug would face commercialization, competition, and reimbursement hurdles. Partnership milestones and royalties may never materialize if the underlying programs stall.
How is vTv Therapeutics Inc. (VTVT) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see vTv Therapeutics Inc.'s investor relations page or your broker.
- Stage: Clinical-stage biotech; no approved products and no meaningful product revenue
- Market cap: Micro-cap, roughly in the low hundreds of millions of dollars (varies sharply with trial news)
- Lead program: Cadisegliatin (TTP399), oral glucokinase activator, in the CATT1 Phase 3 trial for type 1 diabetes; FDA Breakthrough Therapy designation
- Cash position: ~$98 million as of Q1 2026, aided by a $20 million Newsoara upfront; described as sufficient toward CATT1 topline data
- Recent revenue: Mainly licensing and milestone payments (e.g., the Newsoara HPP737 deal), not recurring product sales
- Earnings: Typically operating losses as it funds trials; occasional reported profit can stem from one-time license payments, not operations
Figures are approximate and tied to the asOf date; verify live numbers (current cash, burn rate, market cap, share count, and CATT1 trial timing) before acting. Standard valuation metrics like P/E do not meaningfully apply to a pre-revenue biotech; the stock is valued on the probability-weighted potential of its pipeline. Any occasional reported quarterly profit is usually driven by one-off licensing income rather than a sustainable business, so cash runway and trial milestones matter far more than reported earnings.
Who competes with vTv Therapeutics Inc. (VTVT)?
Type 1 diabetes adjunctive and adjacent therapies
In type 1 diabetes, cadisegliatin would be an oral add-on to insulin, an area with few approved oral options. It competes conceptually with insulin therapy itself and with other companies researching adjunctive treatments, as well as with the broader diabetes drug field, including SGLT and incretin-based approaches that have been studied in or around type 1 and type 2 diabetes.
Large diabetes drugmakers
The diabetes market is dominated by large players such as Novo Nordisk and Eli Lilly, whose insulins and blockbuster incretin (GLP-1) drugs set the competitive and pricing backdrop. vTv is not a direct rival at scale, but any oral type 1 therapy it commercializes would enter a market shaped by these giants and their vast resources and physician relationships.
Other small and clinical-stage biotechs
As a speculative micro-cap, vTv competes with many other small clinical-stage biotechs for investor capital, partnership deals, and clinical talent. Investors weighing VTVT typically compare it against other early-stage drug developers with binary catalysts, where success depends on trial data and where financing risk and volatility are common to the whole group.
How to invest in vTv Therapeutics Inc. (VTVT)
There are three common ways to get VTVT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so VTVT sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where VTVT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on vTv Therapeutics Inc. (VTVT)
vTv Therapeutics is a speculative micro-cap biotech built around cadisegliatin, an oral drug in Phase 3 for type 1 diabetes with Breakthrough Therapy status. Recent licensing cash extended its runway toward key trial data, but this is a binary, pre-revenue bet where success or failure of a single readout can dominate the outcome.
Build a basket around VTVT with Walnut
Use vTv Therapeutics Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is VTVT a good stock to buy right now?
+
This depends on your goals, time horizon, and risk tolerance, and it is not investment advice. VTVT is a speculative, pre-revenue micro-cap biotech whose value hinges on clinical trial results, especially the CATT1 Phase 3 study for cadisegliatin. The upside case is a potential first-in-class oral therapy with Breakthrough status and recent licensing cash; the downside is binary trial failure, dilution risk, and high volatility. It suits only investors comfortable with substantial risk of loss.
What does vTv Therapeutics do?
+
vTv Therapeutics is a clinical-stage biopharmaceutical company developing new medicines, with no approved products yet. Its lead candidate is cadisegliatin, an oral drug being tested as an add-on to insulin for type 1 diabetes. As a clinical-stage company, its value depends on the potential of drugs still in trials rather than on current sales, so its future rests on trial outcomes and regulatory decisions.
What is cadisegliatin (TTP399)?
+
Cadisegliatin, formerly called TTP399, is an oral small-molecule, liver-selective glucokinase activator. vTv is developing it as a potential first-in-class oral adjunctive treatment for type 1 diabetes, taken alongside insulin. It showed positive Phase 2 results, improving blood-sugar control and time in range, and it has FDA Breakthrough Therapy designation. It is now in the CATT1 Phase 3 trial, the company's most important program.
What stage is vTv's lead drug in?
+
Cadisegliatin is in a US Phase 3 trial called CATT1 for type 1 diabetes, with enrollment expected to complete in the second half of 2026. Phase 3 is the final major stage of testing before a company can seek FDA approval. The drug is also being studied in type 2 diabetes through a Phase 2 collaboration in the United Arab Emirates, broadening its potential use if trials succeed.
How does vTv fund itself without product revenue?
+
As a pre-revenue biotech, vTv funds its trials from its cash reserves, licensing payments, and periodic financings rather than from profits. In early 2026 it received a $20 million upfront payment by amending a licensing deal with Newsoara for its HPP737 drug, which helped lift its cash near $98 million and extend its runway. This kind of non-dilutive partnership cash reduces, but does not eliminate, the need for future fundraising.
What is the Newsoara deal?
+
In February 2026 vTv amended its license agreement with Newsoara Biopharma, granting Newsoara global rights to develop and commercialize vTv's PDE4 inhibitor HPP737. vTv received a $20 million upfront payment, with the potential for up to roughly $115 million in future milestones plus tiered royalties. The deal provided non-dilutive cash to help fund vTv's diabetes programs toward key trial data.
Why is VTVT so volatile?
+
VTVT is a micro-cap, pre-revenue biotech, so its value depends on a small number of drug candidates and can swing sharply on trial data, regulatory news, or financing announcements. The shares can also be thinly traded, which amplifies price moves. Because the outcome is largely binary, tied to whether key trials succeed, the stock can rise or fall dramatically on a single piece of news.
What is Breakthrough Therapy designation?
+
Breakthrough Therapy designation is an FDA status meant to speed the development and review of drugs that may offer substantial improvement over existing treatments for serious conditions. Cadisegliatin received it for type 1 diabetes. The designation can provide more frequent FDA interaction and a faster path, but it is not approval; the drug still must succeed in Phase 3 and clear regulatory review before it can be sold.
What are the main risks of owning VTVT?
+
The central risk is binary failure: a disappointing CATT1 result or an FDA setback could sharply cut the stock, since vTv has no approved products. Financing risk is significant because it funds trials from cash and partnerships, so a runway shortfall could force dilutive share sales. As a thinly traded micro-cap, it is highly volatile. Even if a drug is approved, commercialization, competition from large diabetes drugmakers, and reimbursement remain hurdles.
How can I get exposure to vTv Therapeutics?
+
VTVT trades on the Nasdaq, so you can buy shares or fractional shares at any major US broker, or hold it as a small speculative position within a broader basket. Because it is a high-risk clinical-stage biotech, some broad biotech or small-cap ETFs may hold it in tiny weightings, but direct exposure concentrates the binary trial risk that defines the stock. Position sizing matters given the volatility.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with vTv Therapeutics Inc.'s investor relations page or your broker before making investment decisions.